New research published in JMIR Diabetes demonstrated the real-world effectiveness of the Fitterfly Diabetes digital therapeutic program. The Fitterfly Diabetes CGM digital therapeutic aims to help in the management of glycemic control for people with type 2 diabetes. Led by Shilpa Joshi, Arbinder Singal, and colleagues, the study demonstrated significant improvements in blood glucose levels and […]
Technology
Ascensia expands payment program for Senseonics Eversense E3 CGM
Ascensia Diabetes Care announced today that it expanded the Eversense PASS program for the Senseonics (NYSE:SENS) Eversense E3 CGM. Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable […]
Insulet restructures leadership team to drive growth
Insulet (Nasdaq:PODD) announced today that it reshuffled its organizational structure to accelerate innovation and commercialization. In connection with the reorganization, Bret Christensen, EVP and chief commercial officer, leaves the company today to pursue other opportunities. He agreed to offer consulting services during a transition period. Jim Hollingshead, Insulet’s president and CEO, said Christensen “played an […]
Study supports feasibility of Know Labs non-invasive CGM
Know Labs (NYSE:KNW) today announced the results of a feasibility study comparing its glucose monitoring technology to the Dexcom G6 CGM. The company titled its study “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6.” It’s presenting results today at the American Association of Clinical Endocrinology (AACE) Annual Meeting in […]
Insulet reports 21% sales growth in Q1, raises 2023 guidance
Insulet [WtwhTicker symbol=”PODD”](Nasdaq:PODD)[/WtwhTicker] shares are up on first-quarter results that topped the consensus forecast. Shares of PODD rose more than 3% to 331.60 apiece by midday trading today. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down slightly. The Acton, Massachusetts–based automated insulin delivery technology developer […]
Health Canada licenses Medtronic Guardian 4 CGM sensor for use with MiniMed 780G
Medtronic (NYSE:MDT) announced that it received a license from Health Canada for use of its Guardian 4 with the MiniMed 780G. The licensing enables the use of the next-generation continuous glucose monitor sensor with the next-generation automated insulin pump. MiniMed 780G with Guardian 4, an advanced, hybrid closed-loop system, helps users manage type 1 diabetes. […]
Tandem stock dips after hours on Q1 misses as it teases 2023 product launches
Tandem Diabetes Care (Nasdaq:TNDM) shares ticked down after hours today on first-quarter results that fell shy of the consensus forecast. Shares of TNDM fell 9.9% to $36 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.3%. The […]
UK study backs Dexcom real-time CGM
Dexcom (Nasdaq:DXCM) announced today that a published study in the UK supports its real-time continuous glucose monitoring (rtCGM). San Diego-based Dexcom published its study in Diabetes Therapy. It’s titled “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.” The […]
Dexcom proposes $1B offering of convertible senior notes
Dexcom (Nasdaq:DXCM) today announced that it intends to offer $1 billion in convertible senior notes due in 2028. The continuous glucose monitor (CGM) maker made its private placement to persons reasonably considered qualified institutional buyers. San Diego-based Dexcom also plans to grant the initial purchasers of the notes an option to buy more. Those options […]
Abbott FreeStyle Libre 3 authorized for automated insulin delivery in UK
Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery. Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 […]